No Data
No Data
PepGen Pauses Phase II DMD Trial to Review Safety Data
PepGen to Pause Study in Duchenne Muscular Dystrophy; Shares Down Pre-Bell
PepGen to Participate in Upcoming Investor Conferences
Express News | PepGen Inc - No New Safety Issues Observed in Pgn-Edo51 Program
Express News | PepGen Inc - Data From 10 Mg/Kg Cohort Expected in Q3 2025
Express News | PepGen Announces Update to Phase 2 Connect2-Edo51 Study in Patients With Dmd
Unlock the Full List